Efepoetin alfa
- Generic Name
- Efepoetin alfa
Clinical Trial of Efepoetin Alfa in Healthy Subjects
- First Posted Date
- 2024-07-08
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Genexine, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT06490939
- Locations
- 🇰🇷
Hanyang University Medical Center, Seoul, Korea, Republic of
A Phase 3 Study of Efepoetin Alfa for Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis
Phase 3
Recruiting
- Conditions
- Anemia of Chronic Kidney Disease
- Interventions
- First Posted Date
- 2024-06-20
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- Genexine, Inc.
- Target Recruit Count
- 429
- Registration Number
- NCT06466785
- Locations
- 🇬🇪
Batumi Dialysis and Nephrology Center, Batumi, Georgia
🇬🇪L.Managadze National Center of Urology, Tbilisi, Georgia
🇬🇪Tbilisi Heart And Vascular Clinic, Tbilisi, Georgia
A Study of Efepoetin Alfa in Treating Anaemia Associated With Chronic Kidney Diseases Patient
Phase 3
Completed
- Conditions
- Anaemia Associated With Chronic Kidney Disease
- Interventions
- First Posted Date
- 2019-11-07
- Last Posted Date
- 2023-12-22
- Lead Sponsor
- PT Kalbe Genexine Biologics
- Target Recruit Count
- 391
- Registration Number
- NCT04155125
- Locations
- 🇲🇾
Hospital Raja Perempuan Zainab II, Kota Bharu, Malaysia
🇲🇾Hospital Serdang, Serdang, Malaysia
🇵🇭M3 Dialysis Center, Bacolod City, Philippines
To Evaluate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Erythropoietin
- First Posted Date
- 2011-06-02
- Last Posted Date
- 2012-07-19
- Lead Sponsor
- Green Cross Corporation
- Target Recruit Count
- 100
- Registration Number
- NCT01363934
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath